Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can develop after a person has had a bone marrow or stem cell transplant. In the disease, the host body comes under attack from the donated cells.

What is Graft Versus Host Disease (GVHD)?

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Research into Graft Versus Host Disease (GVHD)

Types of Graft Versus Host Disease (GVHD)

Symptoms and Diagnosis of Graft Versus Host Disease (GVHD)

Treatment of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Latest Graft Versus Host Disease News and Research

Study provides a new paradigm for managing transplant‑related immune complications

Acute graft-versus-host disease (aGVHD) is one of the most serious complications after allogeneic hematopoietic stem cell transplantation (allo‑HSCT).

16 Jan 2026

Recent advances in CAR-NK cell therapy could revolutionze cancer treatment

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.

8 Jan 2026

Expanded donor matching makes stem cell transplants accessible

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker.

10 Dec 2025

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation.

7 Dec 2025

New evidence shows hematopoietic cell transplantation offers durable relief for sickle cell disease

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study.

7 Dec 2025

Study demonstrates a safer strategy for allogeneic stem cell transplants

In preclinical studies, researchers found that priming the immune system with a Treg-expanding therapy before stem cell transplant boosted survival, protected vital organs, and promoted a balanced gut microbiome-offering hope for safer, more effective treatment of blood cancers.

27 Nov 2025

Young donor age proves critical for survival after stem cell transplantation

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT).

21 Nov 2025

New transplant approach resets the immune system to stop Type 1 diabetes

A combination blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely prevented or cured Type 1 diabetes in mice in a study by Stanford Medicine researchers.

18 Nov 2025

Researchers uncover TRAT1's central role in T helper cell function

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the immune system: the protein molecule TRAT1 (T Cell Receptor Associated Transmembrane Adaptor 1) plays a central role in how so-called T helper cells (a specialised subgroup of immune cells) distinguish between attack and self-control - an important mechanism for restraining inflammation and preventing autoimmune diseases. The findings have recently been published in the journal Cell Communication and Signaling.

16 Oct 2025

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment - all without the need to customize treatment for each individual patient.

29 Aug 2025

Targeted microglia replacement shows promise against fatal neurodegenerative conditions

Tay-Sachs and Sandhoff diseases, genetic disorders affecting the brain, have no effective treatment and are typically fatal within the first years of life.

6 Aug 2025

New antibody therapy offers hope for fragile patients with Fanconi anemia

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.

22 Jul 2025

New approach makes mismatched stem cell transplants safer for blood cancer patients

Advances in blood stem cell transplants now make it possible for people with blood cancers to get safe and effective "mismatched" transplants that will potentially cure their disease, new UVA Cancer Center research reveals. The advances will allow far more people to receive the lifesaving treatment.

15 Jul 2025

Partial match stem cell transplants show strong survival rates

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.

26 Jun 2025

Antibiotic use predicts microbiota dysbiosis in preterm infants

Antibiotic use in preterm infants is linked to gut microbiome changes, increasing susceptibility to infections and impacting long-term health outcomes.

11 Jun 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Machine learning model outperforms traditional methods in myelofibrosis risk stratification

A machine learning model generated by a team from the European Society for Blood and Marrow Transplantation (EBMT) outperformed standard statistical models in identifying and stratifying transplant risk for patients with myelofibrosis, according to new research published today in Blood, the American Society of Hematology's flagship journal.

27 Mar 2025

Are Allogeneic CAR-Ts the Future of LBCL Cancer Treatment? - Making Safe, Durable & Effective Universal Cell Therapies a Reality

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell Lymphoma.

From Hanson Wade Group - 7th Allogeneic Cell Therapies Summit 4 Mar 2025

European project aims to develop new treatments for rare eye diseases

The Ocular Neurobiology laboratory at the Institute for Neurosciences, a joint center of Miguel Hernández University (UMH) in Elche and the Spanish National Research Council (CSIC), is participating in the European project RESTORE VISION, an ambitious initiative aimed at developing new treatments for rare eye diseases such as aniridia and neurotrophic keratopathy.

28 Feb 2025